首页> 外文期刊>International journal of antimicrobial agents >Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model
【24h】

Effect of antibiotic co-administration on young and mature biofilms of cystic fibrosis clinical isolates: the importance of the biofilm model

机译:抗生素共同给药对囊性纤维化临床分离株年轻和成熟生物膜的影响:生物膜模型的重要性

获取原文
获取原文并翻译 | 示例
       

摘要

The prognosis of patients with cystic fibrosis (CF) has improved dramatically over the last three decades although the majority of patients still die in early adulthood. Infection with Pseudomonas aeruginosa has generally been associated with declining lung function and increased mortality in patients. This study aimed to investigate the in vitro activity of tobramycin/clarithromycin combination on biofilms of clinical isolates of P. aeruginosa,meticillin-susceptible and -resistant Staphylococcus aureus, and Burkholderia cepacia. First, the impact of antibiotic co-administration on biofilms at different stages of maturation, i.e. during early formation and on 24-h-old and 12-day-old biofilms, was compared. The 24-h-old biofilms were found to behave differently compared with those aged 12 days, which were more resistant to antibiotics. A kinetic study of antibiotic co-administration twice a day for 9 days on 12-day-old P. aeruginosa biofilms was then performed to simulate the effect of treatment of CF patients by inhaled tobramycin through aerosolisation (TOBI). The results obtained support a synergistic activity of tobramycin/clarithromycin combination on biofilms of P. aeruginosa PY02 and PA01, with a logarithmic bacterial decrease of 3.37 and 3.96, respectively. On the other hand, increased resistance to each of the antibacterial agents used alone was observed. This study highlights the importance of the biofilm stage for in vitro investigations and enabled the development of an in vitro model of mature biofilm that is more appropriate to mimic in vivo conditions in CF patients.
机译:在过去的三十年中,囊性纤维化(CF)患者的预后有了显着改善,尽管大多数患者仍死于成年早期。铜绿假单胞菌感染通常与肺功能下降和患者死亡率增加有关。这项研究旨在调查妥布霉素/克拉霉素组合在体外对铜绿假单胞菌,对甲氧西林敏感和耐药的金黄色葡萄球菌和洋葱伯克霍尔德菌的临床分离株生物膜上的活性。首先,比较了抗生素共同给药对不同成熟阶段生物膜的影响,即在早期形成过程中以及对24小时和12天龄的生物膜的影响。发现24小时长的生物膜与12天大的生物膜相比表现不同,它们对抗生素的抵抗力更高。然后对12天大的铜绿假单胞菌生物膜进行每天两次抗生素共给药,共9天的动力学研究,以模拟通过雾化吸入妥布霉素(TOBI)吸入治疗CF患者的效果。获得的结果支持妥布霉素/克拉霉素组合在铜绿假单胞菌PY02和PA01的生物膜上的协同活性,对数细菌减少分别为3.37和3.96。另一方面,观察到对单独使用的每种抗菌剂的抗性增加。这项研究强调了生物膜阶段对于体外研究的重要性,并使成熟的生物膜体外模型的开发成为可能,该模型更适合于模拟CF患者的体内状况。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号